{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:01Z","timestamp":1791919621022,"version":"4.3.4"},"reference-count":149,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010037","name":"Chongqing Youth Science and Technology Talent Training Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012397","name":"Army Medical University","doi-asserted-by":"publisher","award":["XZ-2019-505-042"],"award-info":[{"award-number":["XZ-2019-505-042"]}],"id":[{"id":"10.13039\/501100012397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bbcan.2023.188907","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T12:09:23Z","timestamp":1683720563000},"page":"188907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["An overview of the research progress of BRCA gene mutations in breast cancer"],"prefix":"10.1016","volume":"1878","author":[{"given":"Andi","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.bbcan.2023.188907_bb0010","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070","volume":"18","author":"Soerjomataram","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Pt 20","key":"10.1016\/j.bbcan.2023.188907_bb0015","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1242\/jcs.114.20.3591","article-title":"Functions of BRCA1 and BRCA2 in the biological response to DNA damage","volume":"114","author":"Venkitaraman","year":"2001","journal-title":"J. Cell Sci."},{"issue":"23","key":"10.1016\/j.bbcan.2023.188907_bb0020","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"146","key":"10.1016\/j.bbcan.2023.188907_bb0025","first-page":"30","article-title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","volume":"2021","author":"Pujol","year":"1990","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.bbcan.2023.188907_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.553080","article-title":"Surgical and systemic treatment of hereditary breast cancer: a mini-review with a focus on BRCA1 and BRCA2 mutations","volume":"10","author":"Pouptsis","year":"2020","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.188907_bb0035","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","article-title":"Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic","volume":"27","author":"Winter","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"5182","key":"10.1016\/j.bbcan.2023.188907_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science."},{"issue":"6559","key":"10.1016\/j.bbcan.2023.188907_bb0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.bbcan.2023.188907_bb0055","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"8899","key":"10.1016\/j.bbcan.2023.188907_bb0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet Lond. Engl."},{"issue":"15","key":"10.1016\/j.bbcan.2023.188907_bb0065","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","author":"Breast Cancer Linkage Consortium","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.bbcan.2023.188907_bb0070","doi-asserted-by":"crossref","DOI":"10.4172\/1948-5956.1000234","article-title":"Molecular mechanisms of PARP inhibitors in BRCA-related Ovarian cancer","volume":"05","author":"Cortesi","year":"2013","journal-title":"J. Cancer Sci. Ther."},{"issue":"13","key":"10.1016\/j.bbcan.2023.188907_bb0075","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA."},{"issue":"11","key":"10.1016\/j.bbcan.2023.188907_bb0080","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2023.188907_bb0085","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies - PubMed","volume":"725","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.bbcan.2023.188907_bb0090","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2023.188907_bb0095","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.bbcan.2023.188907_bb0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","article-title":"Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers","volume":"34","author":"van den Broek","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-016-3766-3","article-title":"Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations","volume":"156","author":"Yao","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"5645","key":"10.1016\/j.bbcan.2023.188907_bb0110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York breast cancer study group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/djj012","article-title":"Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920\u20132000","volume":"98","author":"Tryggvadottir","year":"2006","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2023.188907_bb0120","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies - PubMed","volume":"725","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"9","key":"10.1016\/j.bbcan.2023.188907_bb0125","first-page":"741","article-title":"Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA21","volume":"8","author":"Hopper","year":"1999","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0130","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10549-015-3495-z","article-title":"Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2","volume":"152","author":"Park","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"24","key":"10.1016\/j.bbcan.2023.188907_bb0135","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1056\/NEJMra1707939","article-title":"Breast cancer in men","volume":"378","author":"Giordano","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijc.30692","article-title":"The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2,991 patients and 1,043 controls by next-generation sequencing","volume":"141","author":"Lang","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2023.188907_bb0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ejhg.2015.196","article-title":"BRCA1\/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study","volume":"24","author":"H\u00f8berg-Vetti","year":"2016","journal-title":"Eur. J. Hum. Genet EJHG."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0150","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-006-9378-6","article-title":"Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil","volume":"103","author":"Gomes","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1897-4287-12-11","article-title":"Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medell\u00edn, Colombia","volume":"12","author":"Hern\u00e1ndez","year":"2014","journal-title":"Hered Cancer Clin. Pract."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0160","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/cge.12505","article-title":"Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru","volume":"88","author":"Abugattas","year":"2015","journal-title":"Clin. Genet."},{"issue":"7","key":"10.1016\/j.bbcan.2023.188907_bb0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103672","article-title":"Prevalence of BRCA1\/2 germline mutations in 21\u00a0401 families with breast and ovarian cancer","volume":"53","author":"Kast","year":"2016","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0170","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1590\/S1516-31802005000400007","article-title":"Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history","volume":"123","author":"Dufloth","year":"2005","journal-title":"Sao Paulo Med. J. Rev. Paul Med."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10689-012-9578-7","article-title":"The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study","volume":"12","author":"Han","year":"2013","journal-title":"Familial Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13058-020-01349-9","article-title":"Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study","volume":"22","author":"O\u2019Shaughnessy","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0185","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12885-020-06948-5","article-title":"Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a meta-analysis and systematic review","volume":"20","author":"Mohyuddin","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2023.188907_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156789","article-title":"Prevalence and prognostic role of BRCA1\/2 variants in unselected chinese breast cancer patients","volume":"11","author":"Zhong","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0195","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10549-016-3902-0","article-title":"Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer","volume":"158","author":"Zhang","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.bbcan.2023.188907_bb0200","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00432-017-2465-8","article-title":"Analysis of BRCA1\/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing","volume":"143","author":"Li","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.bbcan.2023.188907_bb0205","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","article-title":"Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients","volume":"23","author":"Sun","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.31601","article-title":"Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer","volume":"144","author":"Li","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2023.188907_bb0215","first-page":"9420","article-title":"Multicenter cross-sectional screening of the BRCA gene for Chinese high hereditary risk breast cancer populations","volume":"15","author":"Wei","year":"2018","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0220","first-page":"181","article-title":"BRCA1 and BRCA2 mutations in women from Shanghai China","volume":"13","author":"Suter","year":"2004","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-007-9708-3","article-title":"The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified","volume":"110","author":"Li","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-011-1596-x","article-title":"Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer","volume":"132","author":"Zhang","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.bbcan.2023.188907_bb0235","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/87876","article-title":"Breast cancer genetics: what we know and what we need","volume":"7","author":"Nathanson","year":"2001","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0240","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","article-title":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and\/or ovarian cancer syndrome testing","volume":"145","author":"Sharma","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2023.188907_bb0245","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/CLEP.S206949","article-title":"A systematic review of the international prevalence of BRCA mutation in breast cancer","volume":"11","author":"Armstrong","year":"2019","journal-title":"Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0250","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdv592","article-title":"Genetic testing in a cohort of young patients with HER2-amplified breast cancer","volume":"27","author":"Eccles","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2023.188907_bb0255","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1002\/cncr.29572","article-title":"High incidence of germline BRCA mutation in patients with ER low-positive\/PR low-positive\/HER-2 neu negative tumors","volume":"121","author":"Sanford","year":"2015","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0260","first-page":"134","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"40","key":"10.1016\/j.bbcan.2023.188907_bb0265","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004975","article-title":"Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis","volume":"95","author":"Baretta","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"43","key":"10.1016\/j.bbcan.2023.188907_bb0270","doi-asserted-by":"crossref","first-page":"70113","DOI":"10.18632\/oncotarget.12158","article-title":"BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0275","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.188907_bb0280","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive services task force recommendation statement","volume":"322","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0285","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","article-title":"BRCA1\/2 testing: therapeutic implications for breast cancer management","volume":"119","author":"Tung","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2023.188907_bb0290","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaoncol.2015.3048","article-title":"Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study","volume":"1","author":"Armstrong","year":"2015","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0295","first-page":"728","article-title":"Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral","volume":"22","author":"Bellcross","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.188907_bb0300","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.22092","article-title":"Patient and clinician decision support to increase genetic counseling for hereditary breast and ovarian cancer syndrome in primary care: a cluster randomized clinical trial","volume":"5","author":"Kukafka","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.bbcan.2023.188907_bb0305","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1200\/JCO.1996.14.5.1730","article-title":"Genetic testing for cancer susceptibility, Adopted on February 20, 1996","volume":"14","author":"Statement of the American Society of Clinical Oncology","year":"1996","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0310","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12282-021-01312-2","article-title":"Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis","volume":"29","author":"Wang","year":"2022","journal-title":"Breast Cancer Tokyo Jpn."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0315","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-014-2890-1","article-title":"Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis","volume":"144","author":"Valachis","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0320","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/SLA.0000000000002804","article-title":"Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1\/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients","volume":"270","author":"van den Broek","year":"2019","journal-title":"Ann. Surg."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0325","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10549-019-05199-8","article-title":"Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China","volume":"175","author":"Cao","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0330","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6259","article-title":"Comparison of survival after breast-conserving therapy vs mastectomy among patients with or without the BRCA1\/2 variant in a large series of unselected chinese patients with breast cancer","volume":"4","author":"Wan","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bbcan.2023.188907_bb0335","series-title":"Breast Cancer","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2022"},{"issue":"12","key":"10.1016\/j.bbcan.2023.188907_bb0340","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.188907_bb0345","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1002\/ijc.32918","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients","volume":"146","author":"Su","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2023.188907_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ."},{"issue":"15","key":"10.1016\/j.bbcan.2023.188907_bb0355","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review","volume":"22","author":"Li","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2023.188907_bb0360","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","article-title":"Contralateral prophylactic mastectomy (CPM) consensus statement from the American society of breast surgeons: data on CPM outcomes and risks","volume":"23","author":"Boughey","year":"2016","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.188907_bb0365","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrclinonc.2010.175","article-title":"The role of BRCA mutation testing in determining breast cancer therapy","volume":"7","author":"Trainer","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.188907_bb0370","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jnci\/djq018","article-title":"Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients","volume":"102","author":"Bedrosian","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2023.188907_bb0375","article-title":"Prophylactic mastectomy for the prevention of breast cancer","volume":"11","author":"Lostumbo","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"19","key":"10.1016\/j.bbcan.2023.188907_bb0380","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1200\/JCO.2005.10.080","article-title":"Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project","volume":"23","author":"Herrinton","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.188907_bb0385","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","article-title":"Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group","volume":"26","author":"Metcalfe","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2023.188907_bb0390","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1245\/s10434-010-1136-7","article-title":"Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer","volume":"17","author":"Boughey","year":"2010","journal-title":"Ann. Surg. Oncol."},{"issue":"35","key":"10.1016\/j.bbcan.2023.188907_bb0395","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Graeser","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0400","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamasurg.2017.3422","article-title":"Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study","volume":"153","author":"Jakub","year":"2018","journal-title":"JAMA Surg."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0405","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/jama.2018.18942","article-title":"Risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers: a complex discussion","volume":"321","author":"Domchek","year":"2019","journal-title":"JAMA."},{"issue":"12","key":"10.1016\/j.bbcan.2023.188907_bb0410","doi-asserted-by":"crossref","first-page":"E524","DOI":"10.3390\/cancers10120524","article-title":"BRCA mutations and breast cancer prevention","volume":"10","author":"Kotsopoulos","year":"2018","journal-title":"Cancers."},{"key":"10.1016\/j.bbcan.2023.188907_bb0415","first-page":"CD002748","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","volume":"4","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7381","key":"10.1016\/j.bbcan.2023.188907_bb0420","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0425","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0430","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nm0311-283","article-title":"Targeting the missing links for cancer therapy","volume":"17","author":"Polyak","year":"2011","journal-title":"Nat. Med."},{"issue":"6330","key":"10.1016\/j.bbcan.2023.188907_bb0435","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science."},{"issue":"9","key":"10.1016\/j.bbcan.2023.188907_bb0440","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.188907_bb0445","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2023.188907_bb0450","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","article-title":"PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification","volume":"53","author":"Langelier","year":"2018","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.188907_bb0455","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2023.188907_bb0460","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000361","article-title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","volume":"3","author":"Poggio","year":"2018","journal-title":"ESMO Open."},{"issue":"152","key":"10.1016\/j.bbcan.2023.188907_bb0470","first-page":"68","article-title":"Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis","volume":"2021","author":"Gelmon","year":"1990","journal-title":"Eur. J. Cancer Oxf. Engl."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0475","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0480","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0485","doi-asserted-by":"crossref","first-page":"450","DOI":"10.18632\/aging.202152","article-title":"Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis","volume":"13","author":"Wang","year":"2020","journal-title":"Aging."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) - PubMed","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.188907_bb0495","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1200\/JCO.19.01304","article-title":"Neoadjuvant Talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant - PubMed","volume":"38","author":"Litton","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2023.188907_bb0500","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2021.39.15_suppl.505","article-title":"Neoadjuvant talazoparib in patients with germline BRCA1\/2 (gBRCA1\/2) mutation-positive, early HER2-negative breast cancer (BC): results of a phase 2 study","volume":"39","author":"Litton","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0505","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0510","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2023.188907_bb0515","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-LB-273","article-title":"Abstract LB-273: a head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles","volume":"78","author":"Leo","year":"2018","journal-title":"Cancer Res."},{"issue":"25","key":"10.1016\/j.bbcan.2023.188907_bb0520","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2023.188907_bb0525","series-title":"Quality of life results from OlympiA: a phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1\/2 mutations and high-risk HER-2 negative early breast cancer","author":"Ganz","year":"2023"},{"issue":"26","key":"10.1016\/j.bbcan.2023.188907_bb0530","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.21.01532","article-title":"Hereditary breast cancer guideline expert panel. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update","volume":"39","author":"Tung","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2023.188907_bb0535","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS619","article-title":"PARTNER: a randomized, phase II\/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and\/or germline BRCA-mutated breast cancer","volume":"40","author":"Drewett","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2023.188907_bb0540","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS1114","article-title":"A phase II clinical trial to analyze olaparib response in patients with BRCA1 and\/or BRCA2 promoter methylation with advanced breast cancer (GEICAM\/2015-06 COMETA-Breast study)","volume":"36","author":"De La Haba","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2023.188907_bb0545","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS1112","article-title":"VIOLETTE: a randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC)","volume":"37","author":"Tutt","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2023.188907_bb0550","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.1092","article-title":"RUBY: a phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD)","volume":"37","author":"Patsouris","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.bbcan.2023.188907_bb0555","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0560","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1897-4287-7-8","article-title":"Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?","volume":"7","author":"Imyanitov","year":"2009","journal-title":"Hered Cancer Clin. Pract."},{"key":"10.1016\/j.bbcan.2023.188907_bb0565","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s40001-022-00839-0","article-title":"Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis","volume":"27","author":"Lin","year":"2022","journal-title":"Eur. J. Med. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0570","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.188907_bb0575","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2023.188907_bb0580","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/annonc\/mdy209","article-title":"Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.188907_bb0585","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)\u2020","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.188907_bb0590","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0595","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.188907_bb0600","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djx258","article-title":"Comparison of neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results","volume":"110","author":"Gluz","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.bbcan.2023.188907_bb0605","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbcan.2023.188907_bb0610","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-018-03210-2","article-title":"A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer","volume":"9","author":"Wu","year":"2018","journal-title":"Nat. Commun."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2023.188907_bb0615","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.507","article-title":"TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC\u2014Evaluating the homologous recombination deficiency (HRD) biomarker","volume":"37","author":"Mayer","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.bbcan.2023.188907_bb0620","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.19.03292","article-title":"TBCRC 031: randomized Phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-Negative Breast Cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0625","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-008-0128-9","article-title":"Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","volume":"115","author":"Byrski","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0630","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.188907_bb0635","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0640","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12032-015-0514-1","article-title":"High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation","volume":"32","author":"Moiseyenko","year":"2015","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0645","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1078-0432.CCR-16-0162","article-title":"Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"15","key":"10.1016\/j.bbcan.2023.188907_bb0650","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"25","key":"10.1016\/j.bbcan.2023.188907_bb0655","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1056\/NEJMcibr1710161","article-title":"Signatures of DNA-Repair deficiencies in breast cancer","volume":"377","author":"Turner","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2023.188907_bb0660","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdy049","article-title":"Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers","volume":"29","author":"Birkbak","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.188907_bb0665","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.188907_bb0670","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.annonc.2021.09.003","article-title":"Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial","volume":"32","author":"Llop-Guevara","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2023.188907_bb0675","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","article-title":"Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a Phase 3 randomized clinical trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol."},{"issue":"22","key":"10.1016\/j.bbcan.2023.188907_bb0680","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2023.188907_bb0685","author":"Schmid"},{"issue":"1","key":"10.1016\/j.bbcan.2023.188907_bb0690","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13643-020-01306-9","article-title":"Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis","volume":"9","author":"Litvin","year":"2020","journal-title":"Syst. Rev."},{"issue":"4_Supplement","key":"10.1016\/j.bbcan.2023.188907_bb0695","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P4-06-13","article-title":"Abstract P4-06-13: Programmed death-1 and programmed death-ligand 1 expression in sporadic breast cancer compared to BRCA germline mutation related breast cancer and male breast cancer","volume":"79","author":"Manson","year":"2019","journal-title":"Cancer Res."},{"issue":"4_Supplement","key":"10.1016\/j.bbcan.2023.188907_bb0700","volume":"79","author":"Emens","year":"2019","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.bbcan.2023.188907_bb0705","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1200\/JCO.2018.78.2425","article-title":"DNA repair deficiency and immunotherapy response","volume":"36","author":"Mouw","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2023.188907_bb0710","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2023.188907_bb0715","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz253.017","article-title":"1191O - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)","volume":"30","author":"Domchek","year":"2019","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.188907_bb0720","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"issue":"4_Supplement","key":"10.1016\/j.bbcan.2023.188907_bb0725","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P1-14-05","volume":"79","author":"Musolino","year":"2019","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2023.188907_bb0730","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10549-018-05127-2","article-title":"BRCA1\/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients","volume":"174","author":"Friedlaender","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2023.188907_bb0735","doi-asserted-by":"crossref","first-page":"viii98","DOI":"10.1093\/annonc\/mdy272.299","article-title":"Efficacy and toxicity of endocrine therapy + cyclin-dependent kinases 4\/6 inhibitors (iCDK4\/6) in metastatic breast cancer patients according to gBRCA status","volume":"29","author":"Bruno","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4_Supplement","key":"10.1016\/j.bbcan.2023.188907_bb0740","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-GS4-08","article-title":"Abstract GS4-08: comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance","volume":"82","author":"Safonov","year":"2022","journal-title":"Cancer Res."},{"issue":"34","key":"10.1016\/j.bbcan.2023.188907_bb0745","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, Node-Positive, High-Risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:00:11Z","timestamp":1777554011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X23000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0304419X23000562"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.188907","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of the research progress of BRCA gene mutations in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.188907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188907"}}